Cambridge, UK and MONTREAL, April 13, 2026 (GLOBE NEWSWIRE) – Epitopea, a transatlantic company specializing in cancer immunotherapy, announced today the appointment of Lisa Butterfield to its scientific advisory board (SAB). A respected figure in the field of immuno-oncology, Dr. Butterfield brings extensive expertise in cancer vaccines, immune profiling, biomarker development, and cellular therapies for solid tumors to Epitopea.
Dr. Butterfield has previously worked at Merck’s Discovery Oncology team in South San Francisco and as an assistant professor of microbiology and immunology at the University of California, San Francisco. She has also held roles at the Parker Institute for Cancer Immunotherapy and the University of Pittsburgh. Dr. Butterfield has authored over 200 peer-reviewed publications and played a leading role in cancer immunotherapy.
“I am particularly excited to translate these discoveries into RNA-based immunotherapies that provide lasting benefits to patients. I look forward to helping the team define its scientific strategy as the company advances towards clinical trials,” said Lisa Butterfield.
Epitopea’s CEO, Dr. Alan C. Rigby, commented on the appointment, highlighting Dr. Butterfield’s expertise in cancer vaccines, tumor immunology, and translational immunotherapy. Her experience in academia, biotechnology, and pharmaceutical research will be valuable as Epitopea advances its pipeline and moves its flagship program, CryptiVax-MC-1001, into clinical trials.
Dr. Butterfield’s appointment strengthens Epitopea’s global advisory board, supporting the development of its RNA-based cancer immunotherapies targeting hard-to-treat solid tumors.
About Epitopea
Epitopea is a transatlantic company specializing in anticancer immunotherapy, developing RNA-based therapies for difficult-to-treat solid tumors. Epitopea’s pipeline is based on Cryptigen-MC tumor-specific antigens identified through the CryptoMap-MC platform, which uncovers aberrantly expressed antigens from previously uncharacterized regions of the genome.
The company’s lead candidate, CryptiVax-MC-1001, is a mRNA therapeutic vaccine currently in development for high-grade ovarian cancer. It aims to induce targeted immune responses using a selection of tumor-specific antigens, covering a wide range of patients with limited therapeutic options.
Epitopea, supported by leading life sciences investors, operates from Cambridge, UK, and Montreal, Canada. For more information, visit www.epitopea.com and follow the company on LinkedIn.
For further information
Epitopea Dr. Alan C. Rigby – CEO Alan.Rigby@epitopea.com
Scius Communications (for Epitopea) Katja Stout +44 7789 435990 katja@sciuscommunications.com Daniel Gooch +44 7747 875479 daniel@sciuscommunications.com
/t:r(unknown)/filters:format(jpeg)/radios/vibration/importrk/news/original/41109.jpeg "Vianney finishes his cabin and is already preparing his return to music")
